Core Insights - Profusa, Inc. has entered into a collaboration with Mayo Clinic to accelerate the regulatory approval and commercialization of its Lumee™ wearable continuous tissue oxygen monitoring product [1][2] - The partnership aims to explore high-impact clinical applications for Profusa's oxygen monitoring technologies, targeting areas such as cardiovascular, renal, multi-organ, and orthopedic applications [1][2] - The Lumee technology, which has received over $100 million in investment and over a decade of development, is positioned as a first-of-its-kind platform for continuous, real-time measurement of tissue oxygen [2] Company Overview - Profusa is a commercial stage digital health company based in Berkeley, California, focused on developing tissue-integrated sensors that provide actionable, medical-grade data for personal and medical use [4] - The company aims to offer long-lasting, injectable, and affordable biosensors, along with an intelligent data platform, to deliver personalized biochemical signatures that clinicians can trust [4] Collaboration Details - The collaboration with Mayo Clinic will support the commercialization of Lumee technology for critical limb ischemia in the U.S. and aims to develop new products to expand the market and therapeutic reach of oxygen tissue monitoring technology [1][2] - Mayo Clinic's involvement includes leveraging Profusa's innovative platform to address unmet clinical challenges, particularly in monitoring beyond subcutaneous tissue [2]

Core Insights - Profusa, Inc. is set to present findings from its pilot clinical study on tissue oxygen monitoring in peripheral artery disease (PAD) patients at the Leipzig Interventional Course (LINC) 2026, scheduled for January 27-30, 2026 [1] - The company's Lumee technology allows for continuous, real-time measurement of tissue oxygen, aimed for both clinical and home use, with positive feedback received from the U.S.-based clinical study [2] - Profusa is a digital health company focused on developing tissue-integrated sensors that provide actionable, medical-grade data for personal and medical use, emphasizing affordability and long-lasting biosensors [3] Company Overview - Profusa is based in Berkeley, California, and is led by a team of experienced management and a world-class board of directors [3] - The company aims to deliver a personalized biochemical signature that clinicians can trust, utilizing its intelligent data platform [3] - The trademarks "LUMEE," "PROFUSA," and the PROFUSA logo are registered in multiple regions including the United States, Canada, and the European Union [4]

Core Insights - Profusa, Inc. is set to present a Late Breaking Clinical Trial Update on its Lumee™ Oxygen tissue monitoring platform at the Paris Vascular Insights (PVI) 2025 conference, highlighting its innovative technology for continuous monitoring of tissue oxygen in patients with peripheral artery disease [1][2] - The Lumee technology allows for real-time measurement of tissue oxygen levels directly within the body, representing a significant advancement in biochemistry monitoring for both clinical and home use [2][3] - Profusa aims to provide personalized biochemical data through its long-lasting, injectable biosensors, which are designed to deliver actionable medical-grade information for both personal and medical applications [3] Presentation Details - The presentation titled "Monitoring Tissue Oxygen Dynamics with a Novel Implantable Hydrogel Sensor in Patients with Peripheral Arterial Disease (PAD)" will be delivered by Dr. Peter Schneider on December 13, 2025, at 1pm CET [2] - The event will take place at the Carrousel du Louvre in Paris, France, showcasing the latest innovations in vascular and endovascular surgery [2] Company Overview - Profusa is based in Berkeley, California, and is recognized for its pioneering work in developing tissue-integrated sensors that continuously transmit reliable biochemical data [3] - The company is led by a team of experienced professionals and aims to create a new generation of affordable biosensors that enhance patient care through personalized data [3]

Core Insights - Profusa, Inc. has expanded its commercial footprint in Europe for its Lumee Oxygen platform by signing a letter of intent with Angiopro GmbH, targeting initial markets such as Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia [1][3] - The partnership with Angiopro enhances Profusa's distributor channel coverage to approximately 35% of the European Union population, facilitating around 300,000 annual endovascular procedures [1][3] - Profusa's Lumee platform technology addresses a global market estimated at over $10.5 billion across three indications: peripheral artery disease, chronic wounds, and critical limb ischemia [3] Company Overview - Profusa is a commercial stage digital health company based in Berkeley, California, focused on developing tissue-integrated sensors that provide continuous, actionable medical-grade data [4] - The company aims to deliver long-lasting, injectable, and affordable biosensors, creating a personalized biochemical signature for individuals [4] Partnership Details - Angiopro GmbH is a specialized MedTech distributor with expertise in cardiovascular technologies, aiming to enhance patient care and drive commercial success [2] - The collaboration is expected to leverage Angiopro's marketing, sales infrastructure, and regulatory expertise to establish a strong foundation for long-term growth with Profusa [2]